NCT06713863 Intervention Effectiveness Study of BEtter AT LEarning (BEATLE)- Digital Neuropsychological Rehabilitation Program
| NCT ID | NCT06713863 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Helsinki University Central Hospital |
| Condition | Dyslexia, Developmental |
| Study Type | INTERVENTIONAL |
| Enrollment | 312 participants |
| Start Date | 2025-05-01 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 312 participants in total. It began in 2025-05-01 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the effectiveness of BEATLE with clinical samples of patients diagnosed with Developmental Language Disorder (DLD), Dyslexia, and Mixed Specific Developmental Disorder. A randomized controlled trial with a waitlist design will be employed. The objective is to assess potential changes in perceived self-efficacy, self-compassion, executive functioning, and attitudes toward learning as reported by the participants, their guardians (parents), and teachers. Additionally, this study aims to examine the correlation between the usage of the Digital Care Pathway (DCP) and its effectiveness.
Eligibility Criteria
For inclusion, the International Classification of Diseases 10th edition (ICD-10; WHO, 2018) diagnostic criteria accompanied with Finnish Current Care Guidelines will be used as follows: Developmental Language Disorder Verbal reasoning skills (Verbal Reasoning Index = VCI) 1.5 standard deviations lower than average (\< 78 Index points) Intact non-verbal reasoning skills (Perceptual Reasoning Index = PRI) \> 84 index points) Normal or fixed to normal hearing and vision Adequate skills in Finnish: Finnish either as a native language, major household language or adequate reported performance in Finnish school system. Dyslexia Measured reading accuracy and comprehension two standard deviations (-2 standard deviations) lower than anticipated when the chronological age and IQ have been taken into account Normal of fixed to normal hearing and vision Adequate skills in Finnish: Finnish either as a native language, major household language or adequate reported performance in Finnish school system. Mixed Developmental Disorder Wide developmental and learning difficulties (69 \< PRI \< 84, 69 \< VCI \< 84) Normal or fixed to normal hearing and vision Adequate skills in Finnish: Finnish either as a native language, major household language or adequate reported performance in Finnish school system. Exclusion Criteria: All exclusion criteria will be addressed individually. If a respondent fulfills one or more of the exclusion criteria, the respondent will be dropped out. Exclusion criteria are formed as follows: Suspicion of mild intellectual disability Both verbal and non-verbal reasoning skills more than two standard deviations lower than average (VCI \& PRI \< 70) Weak (-2 Standard Deviations) performance on both subtests representing fluid intelligence (Wechsler's Intelligence Scale for Children IV (WISC-IV): Matrix reasoning and Picture concepts) Diagnosis of Autism Spectrum Disorder Untreated Attention-Deficit Hyperactivity Disorder Unable to adequately use a a computer and/or a smartphone
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06713863 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, up to 16 Years, studying Dyslexia, Developmental. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06713863 currently recruiting?
Yes, NCT06713863 is actively recruiting participants. Contact the research team at samuel.hannukkala@hus.fi for enrollment information.
Where is the NCT06713863 trial being conducted?
This trial is being conducted at Helsinki, Finland, Helsinki, Finland.
Who is sponsoring the NCT06713863 clinical trial?
NCT06713863 is sponsored by Helsinki University Central Hospital. The trial plans to enroll 312 participants.